Document

CONFIDENTIAL                                             

Exhibit 10.23




[*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed




AMENDMENT No. 9


To the


MULTI-PRODUCT LICENCE AGREEMENT


dated 


31 October 2014


between




LONZA SALES AG
    
and


NGM BIOPHARMACEUTICALS, INC.



























CONFIDENTIAL                             





    This Amendment No. 9 (“Amendment No. 9”) to the Multi-Product License Agreement, dated 31 October 2014, and as amended by Amendment No. 1, dated 28 July 2015 , Amendment No. 2, dated  07 October 2015, Amendment No. 3, dated  26 April 2016, Amendment No. 4, dated  03 October 2017, Amendment No. 5, dated  16 March 2018, Amendment No. 6, dated  06 February  2019, Amendment 7, dated 22 December 2020 and Amendment 8, dated 10 February 2021 (collectively the “Agreement”) is made effective as of the last dates of signatures between the parties (the “Amendment No. 9 Effective Date”); and is
By and Between
LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland ("Lonza"), and
NGM BIOPHARMACEUTICALS, INC., incorporated and registered in the State of Delaware whose registered office is at 333 Oyster Point Blvd., South San Francisco, CA 94080, USA, ("Licensee").
Lonza and Licensee may be independently defined as a “Party” or collectively as the “Parties”.
WHEREAS
A.Lonza and the Licensee entered into the Agreement, pursuant to which Lonza licensed certain Intellectual Property Rights (as therein defined) to the Licensee (“Agreement”).
B.Licensee notified Lonza of the [*] and the Parties therefore agree to update the Products table in Appendix 5 Table A.
C.The Parties wish to amend the terms of the Agreement.
NOW THEREFORE in consideration of the mutual promises and covenants contained herein and other good and valuable consideration the sufficiency of which is acknowledged it is hereby agreed by and between the Parties to amend the Agreement as follows:
1.Unless otherwise defined in this Amendment No. 9, the words and phrases defined in the Agreement shall have the same meanings in this Amendment No. 9.




[*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.        2



CONFIDENTIAL                             



2.Appendix 5 of the Agreement shall be deleted in its entirety and replaced by the Appendix 5 attached hereto in this Amendment No. 9.
3.Save as expressly provided herein through this Amendment No. 9, all terms and conditions of the Agreement shall continue in full force and effect.
AS WITNESS, the hands of the duly authorized representatives of the parties hereto the Amendment No. 9 Effective Date.
									
	SIGNED BY:		/s/ Albert Pereda
	For and on behalf of		
	LONZA SALES AG		
			Associate General Counsel
			                                               Title
			
			Nov 3, 2021
			Date




									
	SIGNED BY:		/s/ Dan Mekic
	For and on behalf of		
	LONZA SALES AG		
			Senior Director, Licensing
			                                               Title
			
			Nov 3, 2021
			Date




									
	SIGNED BY:		/s/ Valerie L. Pierce
	For and on behalf of		
	NGM BIOPHARMACEUTICALS, INC.		
			SVP & General Counsel
			                                               Title
			
			10/14/2021
			Date
			
			












[*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.        3



CONFIDENTIAL                             





APPENDIX 5


PRODUCTS




Table A


												
	Product	Product Name	[*]	[*]
	[*]	[*]	[*]	[*]




*The Licensee shall notify Lonza in writing within a period of [*] days for [*] for each Product per the terms of the Agreement.


[*]


Table B


COMMERCIAL PRODUCTS AND ROYALTIES




												
	Commercial Product	Product Name	Rate of Royalty	Party manufacturing the Product
	Product #1			
	Product #2			
	Product #3			
	Product #4			
	Product #5			
	Product #6			
	Product #7			








[*] = Certain information contained in this document, marked by brackets, has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.        4